Open Medicine (Sep 2018)
Ipragliflozin ameliorates liver damage in non-alcoholic fatty liver disease
- Miyake Teruki,
- Yoshida Sakiko,
- Furukawa Shinya,
- Sakai Takenori,
- Tada Fujimasa,
- Senba Hidenori,
- Yamamoto Shin,
- Koizumi Yohei,
- Yoshida Osamu,
- Hirooka Masashi,
- Kumagi Teru,
- Niiya Tetsuju,
- Miyaoka Hiroaki,
- Masanori Abe,
- Matsuura Bunzo,
- Hiasa Yoichi
Affiliations
- Miyake Teruki
- Department of Gastroenterology and Metabology, Ehime University Graduate School of Medicine, Toon, Ehime791-0295, Japan
- Yoshida Sakiko
- Department of Internal Medicine, Matsuyama Shimin Hospital, Matsuyama, Ehime, Japan
- Furukawa Shinya
- Department of Epidemiology and Preventive Medicine, Ehime University Graduate School of Medicine, Toon, Japan
- Sakai Takenori
- Department of Internal Medicine, Yawatahama General City Hospital, Yawatahama, Japan
- Tada Fujimasa
- Department of Internal Medicine, Saiseikai Matsuyama Hospital, Matsuyama, Japan
- Senba Hidenori
- Department of Internal Medicine, Saiseikai Matsuyama Hospital, Matsuyama, Japan
- Yamamoto Shin
- Department of Lifestyle-related Medicine and Endocrinology, Ehime University Graduate School of Medicine, Toon, Japan
- Koizumi Yohei
- Department of Gastroenterology and Metabology, Ehime University Graduate School of Medicine, Shitsukawa, Toon, Ehime, Japan
- Yoshida Osamu
- Department of Gastroenterology and Metabology, Ehime University Graduate School of Medicine, Shitsukawa, Toon, Ehime, Japan
- Hirooka Masashi
- Department of Gastroenterology and Metabology, Ehime University Graduate School of Medicine, Shitsukawa, Toon, Ehime, Japan
- Kumagi Teru
- Department of Gastroenterology and Metabology, Ehime University Graduate School of Medicine, Shitsukawa, Toon, Ehime, Japan
- Niiya Tetsuju
- Department of Internal Medicine, Matsuyama Shimin Hospital, Matsuyama, Ehime, Japan
- Miyaoka Hiroaki
- Department of Internal Medicine, Saiseikai Matsuyama Hospital, Matsuyama, Japan
- Masanori Abe
- Department of Gastroenterology and Metabology, Ehime University Graduate School of Medicine, Shitsukawa, Toon, Ehime, Japan
- Matsuura Bunzo
- Department of Lifestyle-related Medicine and Endocrinology, Ehime University Graduate School of Medicine, Toon, Japan
- Hiasa Yoichi
- Department of Gastroenterology and Metabology, Ehime University Graduate School of Medicine, Shitsukawa, Toon, Ehime, Japan
- DOI
- https://doi.org/10.1515/med-2018-0059
- Journal volume & issue
-
Vol. 13,
no. 1
pp. 402 – 409
Abstract
There are few effective medications for non-alcoholic steatohepatitis (NASH). We investigated the efficacy of ipragliflozin (selective sodium-glucose cotransporter-2 inhibitor [SGLT2I]) for the treatment of patients with type 2 diabetes mellitus (T2DM) complicated by non-alcoholic fatty liver disease (NAFLD).
Keywords
- selective sodium-glucose cotransporter-2 inhibitor; ipragliflozin
- type 2 diabetes mellitus
- non-alcoholic steatohepatitis
- non-alcoholic fatty liver disease
